Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
Cosentyx has been helping patients since 20151
In 2021, we reached a massively significant milestone that would barely have seemed possible just a few short years ago.2
Watch the video below to see just how far we’ve come…
To learn more about why you should choose Cosentyx, click here
References
- Bloomberg. Novartis Pharma AG: Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic. Available at: https://www.bloomberg.com/press-releases/2022-05-20/novartis-pharma-ag-n... expanded-use-in-childhood-arthritic [Last accessed June 2022].
- Data on File Sec004. Novartis Pharmaceuticals Corp; 2019.
Rate this content:
UK | June 2022 | 218104